Daniel Souery

This study examines the association between CYP2C19 and CYP2D6 metabolic phenotypes and antidepressant response using genotype imputation across 13 studies, finding no significant associations after correction for multiple testing.

The paper cross-validates genotyping methods for CYP2D6 and CYP2C19, finding high concordance for CYP2C19 and feasibility of NGS for CYP2D6 with automated interpretation.

The paper develops a polygenic predictor for treatment-resistant depression using whole exome sequencing and genome-wide genotyping, finding that genetic scores combined with clinical factors improve prediction.

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

The paper evaluates 42 inflammatory markers in MDD cases and controls, finding strong confounding effects and limited predictive power of individual markers for MDD diagnosis.

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.